The Evolving Healthcare System in China Driven by Evidence-Based Decision-Making

New policies and regulations are being developed better to meet the health needs of over a billion people in China. The demand for scientific evidence has increased dramatically, and this requires accurate evaluation of innovations. In this context, health economics and outcomes research (HEOR) is instrumental to evidence-based decision-making and plays a significant role in China’s healthcare reform.
Leveraging real-world evidence and AI technology, HLT provides turnkey solutions to help clients gain entrance to the National Reimbursement Drug List and achieve optimal market access in China. Our services include (but are not limited to) developing value propositions and market access strategies, conducting economic models, generating reimbursement submission packages, and developing innovative pricing and reimbursement strategies.

What we do